Continuation and Safety Assessment of the BELVIQ Cardiovascular Outcomes Trial
An individual clinical development theme involving continuation of the cardiovascular outcomes trial for BELVIQ, an obesity treatment, and confirmation of the primary safety assessment and the non-inferiority of MACE+.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.